ARVINAS, INC. Debt Securities, Available-for-sale, Amortized Cost
ARVINAS, INC. (ARVN) had Debt Securities, Available-for-sale, Amortized Cost of $1.29 billion as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-11-03
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.29B.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $552.34M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $305.45M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $99.60M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-09-30 | $1.29B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $552.34M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $305.45M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $99.60M 10-Q · filed 2021-11-03 |
| 2020-09-30 | $158.50M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $219.44M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $227.33M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $271.55M 10-K · filed 2021-03-01 |
| 2019-09-30 | $178.18M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $147.53M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $146.10M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $184.86M 10-K · filed 2020-03-16 |
| 2018-09-30 | $83.65M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |